Form 8-K - Current report:
SEC Accession No. 0001213900-20-022322
Filing Date
2020-08-14
Accepted
2020-08-14 17:05:57
Documents
4
Period of Report
2020-08-10
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea125571-8k_actiniumpharma.htm 8-K 22086
2 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF ACTINIUM PHARMAC ea125571ex3-1_actinium.htm EX-3.1 14864
3 PRESS RELEASE DATED AUGUST 10, 2020 ea125571ex99-1_actinium.htm EX-99.1 13302
4 GRAPHIC ex99-1_001.jpg GRAPHIC 20184
  Complete submission text file 0001213900-20-022322.txt   79466
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36374 | Film No.: 201106446
SIC: 2834 Pharmaceutical Preparations